Tyler Trent was just 20 years old when he died from osteosarcoma, a rare bone cancer. Now, his cancer cells live on in a lab at Indiana University School of Medicine, helping scientists test new treatments for future patients. At the heart of this effort is a new imaging system developed by physicist David Nolte at Purdue University. It uses lasers, the Doppler effect, and artificial intelligence to see how cancer cells move and respond when exposed to chemotherapy drugs. The goal? To find the best treatment for each patient—fast.
Cancer is not one disease. Every tumor behaves differently, and what works for one person may not work for another. Today, doctors often rely on trial and error, which can waste precious time. Nolte’s biodynamic imaging system could change that. By testing drugs on a patient’s own tumor cells taken during diagnosis, the system can show which drugs slow down or stop cancer cell movement—often within hours.
Right now, the technology is being used to study tumor cells from more than 30 osteosarcoma patients, including Tyler Trent’s. These cells grow in 3D structures that mimic real tumors, giving researchers a more accurate picture of how they’ll respond in the body. At Indiana University, pediatric oncologist Karen Pollok is using Nolte’s prototype to test experimental drugs and combinations, hoping to find faster paths to effective treatments.
The system works by shining a laser into living tumor tissue. As cells move inside, they slightly shift the light’s frequency—a phenomenon known as the Doppler effect, the same physics that makes a siren’s pitch change as it passes by. These tiny shifts create a dynamic image of cellular motion. Cancer drugs alter that motion, and AI algorithms trained on thousands of images can now predict whether a drug will work, based on how the cells respond.
This isn’t just theory. In past tests with bladder cancer patients, the system matched results from traditional clinical outcomes, proving its potential. Now, with osteosarcoma, researchers are pushing further. They’re not just looking for one miracle drug—they’re building a reference library of how different tumors react, so future patients can benefit from what’s already been learned.
For families facing a cancer diagnosis, time is everything. Nolte’s system could cut weeks or months off the search for the right treatment. It’s still in testing, but the vision is clear: a future where every patient gets the drug that’s most likely to work, the first time. And in labs across Indiana, the legacy of a young Purdue student is helping make that future real.
